Lundbeck presents VYEPTI migraine cognitive data at AAN
April 20, 2026 | 10:53
The Danish pharmaceutical company disclosed real-world evidence showing cognitive symptom improvements in patients treated with eptinezumab at the neurology conference.
Mobile Version